HK1170658A1 - 用於治療 體病的 -突觸核蛋白表位之模擬表位的用途 - Google Patents

用於治療 體病的 -突觸核蛋白表位之模擬表位的用途

Info

Publication number
HK1170658A1
HK1170658A1 HK12111092.0A HK12111092A HK1170658A1 HK 1170658 A1 HK1170658 A1 HK 1170658A1 HK 12111092 A HK12111092 A HK 12111092A HK 1170658 A1 HK1170658 A1 HK 1170658A1
Authority
HK
Hong Kong
Prior art keywords
alpha
lewy
mimotopes
treating
body diseases
Prior art date
Application number
HK12111092.0A
Other languages
English (en)
Inventor
Markus Mandler
Harald Weninger
Radmila Santic
Christian Lahsnig
Original Assignee
阿費里斯股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿費里斯股份公司 filed Critical 阿費里斯股份公司
Publication of HK1170658A1 publication Critical patent/HK1170658A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK12111092.0A 2009-08-21 2012-11-05 用於治療 體病的 -突觸核蛋白表位之模擬表位的用途 HK1170658A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0132409A AT508638B1 (de) 2009-08-21 2009-08-21 Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
PCT/AT2010/000303 WO2011020133A1 (en) 2009-08-21 2010-08-20 Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases

Publications (1)

Publication Number Publication Date
HK1170658A1 true HK1170658A1 (zh) 2013-03-08

Family

ID=42940852

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111092.0A HK1170658A1 (zh) 2009-08-21 2012-11-05 用於治療 體病的 -突觸核蛋白表位之模擬表位的用途

Country Status (22)

Country Link
US (1) US8828942B2 (zh)
EP (1) EP2467153B1 (zh)
JP (2) JP2013502379A (zh)
KR (2) KR101517447B1 (zh)
CN (1) CN102596224B (zh)
AT (1) AT508638B1 (zh)
AU (1) AU2010283948B2 (zh)
BR (1) BR112012003800A2 (zh)
CA (1) CA2771429A1 (zh)
CY (1) CY1117582T1 (zh)
DK (1) DK2467153T3 (zh)
ES (1) ES2573662T3 (zh)
HK (1) HK1170658A1 (zh)
HR (1) HRP20160594T1 (zh)
HU (1) HUE027563T2 (zh)
IL (1) IL218207A0 (zh)
MX (1) MX2012002153A (zh)
PL (1) PL2467153T3 (zh)
PT (1) PT2467153E (zh)
RU (1) RU2532351C2 (zh)
SI (1) SI2467153T1 (zh)
WO (1) WO2011020133A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2579042T3 (pl) 2011-10-04 2014-12-31 Affiris Ag Sposób wykrywania przeciwciał swoistych wobec Aß w próbce biologicznej
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
PL3071597T3 (pl) 2013-11-21 2020-11-30 F.Hoffmann-La Roche Ag Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania
JP7378931B2 (ja) 2015-11-03 2023-11-14 エイシー イミューン ソシエテ アノニム ヒト患者における自己抗原に対するワクチン接種法
KR101726549B1 (ko) 2016-06-29 2017-04-12 정상문 모바일 실시간 시뮬레이션 게임에서의 터치 조작 방식
KR102087494B1 (ko) 2018-03-15 2020-03-10 정상문 모바일 실시간 시뮬레이션 게임에서 객체를 표시하는 방법
KR20210110318A (ko) 2018-12-20 2021-09-07 사이바 아게 융합에 의해 변형된 cmv의 바이러스-유사 입자
WO2022024693A1 (ja) 2020-07-29 2022-02-03 国立大学法人東北大学 シヌクレイノパチーを予防又は治療するために使用されるペプチド
CN116261464A (zh) 2020-08-04 2023-06-13 Ac免疫有限公司 免疫原性化合物
EP4323397A1 (en) 2021-04-12 2024-02-21 Saiba AG Modified virus-like particles of bacteriophage ap205
TW202306966A (zh) * 2021-06-18 2023-02-16 日商住友製藥股份有限公司 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物
WO2023152260A1 (en) 2022-02-09 2023-08-17 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines
WO2023161527A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007325595A (ja) * 2000-12-22 2007-12-20 Locomogene Inc 滑膜細胞タンパク質
WO2003045128A2 (en) * 2001-11-21 2003-06-05 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005013889A2 (en) * 2003-05-19 2005-02-17 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
US20070213253A1 (en) 2003-06-22 2007-09-13 Koji Sode Synuclein Mutant Having Aggregation-Inhibitory Activity
WO2006004066A1 (ja) * 2004-07-02 2006-01-12 Locomogene, Inc. S1-5を含有するタンパク質製剤
MX2007001679A (es) * 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CN101052417A (zh) * 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
ES2551604T3 (es) * 2005-12-12 2015-11-20 Ac Immune S.A. Vacuna terapéutica
DK2949666T3 (en) * 2008-12-19 2019-03-25 Biogen Int Neuroscience Gmbh HUMAN ANTI-ALPHA SYNUCLEIN ANTIBODIES

Also Published As

Publication number Publication date
AT508638A1 (de) 2011-03-15
HUE027563T2 (en) 2016-10-28
CY1117582T1 (el) 2017-04-26
EP2467153A1 (en) 2012-06-27
JP2013502379A (ja) 2013-01-24
KR20140141651A (ko) 2014-12-10
DK2467153T3 (en) 2016-06-06
US20120156234A1 (en) 2012-06-21
RU2012110582A (ru) 2013-09-27
AU2010283948A1 (en) 2012-03-29
EP2467153B1 (en) 2016-03-02
MX2012002153A (es) 2012-03-14
CN102596224A (zh) 2012-07-18
AT508638B1 (de) 2011-08-15
IL218207A0 (en) 2012-04-30
PL2467153T3 (pl) 2016-09-30
CN102596224B (zh) 2015-12-09
HRP20160594T1 (hr) 2016-07-29
US8828942B2 (en) 2014-09-09
JP2015038078A (ja) 2015-02-26
CA2771429A1 (en) 2011-02-24
PT2467153E (pt) 2016-06-08
AU2010283948B2 (en) 2015-01-22
ES2573662T3 (es) 2016-06-09
WO2011020133A1 (en) 2011-02-24
KR101517447B1 (ko) 2015-05-28
SI2467153T1 (sl) 2016-07-29
KR20120059562A (ko) 2012-06-08
JP5901714B2 (ja) 2016-04-13
BR112012003800A2 (pt) 2016-11-22
RU2532351C2 (ru) 2014-11-10

Similar Documents

Publication Publication Date Title
HK1170658A1 (zh) 用於治療 體病的 -突觸核蛋白表位之模擬表位的用途
HRP20181512T1 (hr) Mimotopi od alfa-sinukleina i njihova cjepiva za liječenje neurodegenerativnih poremećaja
IL216509A0 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
EP2415359A4 (en) USE OF A PEPTIDE CONFERING A BETTER TASTE
HK1217763A1 (zh) 用於治療疾病的方法
EP2425875A4 (en) MASK COVER
PH12014501685A1 (en) Humanized antibodies that recognize alpha-synuclein
EP2427250A4 (en) THERAPEUTIC BODY STRAP
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
EP2498796A4 (en) TREATMENT OF HEART DISEASES
GB0902040D0 (en) Composition for treatment of skin
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
SI2735316T1 (sl) Novi terapevtski pristopi za zdravljenje nevroinflamatornih stanj
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
EP2512484A4 (en) METHODS FOR THE TREATMENT OF SPEECH DISORDERS
HK1178043A1 (zh) 適用於把蒸氣投放在人體的部分的氣化器
GB0905954D0 (en) Treatment of exacerbations of asthma
GB0908666D0 (en) Treatment of proteostatic disease
TWM386004U (en) Improved structure of incense body
TWM372652U (en) Umbrella capable of covering body

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200820